Aquatic Exercise for Cognition and Mobility in Older Adults

Not Applicable

Completed

• Conditions: Cognitive Change; Aging Well; Mobility Limitation; Gait, Unsteady; Aging Problems
• Interventions: Behavioral: Aquatic Integrated Cognitive Motor Training

• Registration Number: NCT05501249
• Lead Sponsor: Emily Dunlap

Brief Summary

The purpose of this study is to assess the effects of an aquatic exercise program on cognition and physical function of older adults.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-01
• Study First Submitted: 2022-08-10
• Study First Submitted QC: 2022-08-11
• Study First Posted: 2022-08-15
• Primary Completion: 2022-12-12
• Study Completion: 2022-12-12
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-27
• Last Update Posted: 2023-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Able to ambulate 100 ft independently with or without assistive device
• Score greater than or equal to 3 on the Mini-Cog Test
• Stable medical condition within one month prior to the study
• Stable exercise program within one month prior to the study
• Available during study testing and group class times
• COVID-19 vaccination
• Permission from medical provider to participate in the study

Exclusion Criteria

• History of dementia or Alzheimer's
• Contraindication to exercise or pool immersion (e.g., unstable cardiovascular conditions, fever, diarrhea, aqua-phobia)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Aquatic Exercise Group	Aquatic Integrated Cognitive Motor Training	Aquatic class 45 minutes, 3 times a week, for 8 weeks

Primary Outcome Measures

Name	Time	Method
Trail Making Test A and B: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Measure of visual scanning and working memory
Gait Measurements: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	4 gait conditions (single task gait, dual task gait with head turns, dual task gait with head nods, and dual task gait count backwards by serial 7s). Gait measures collected with Strideway Gait Analysis System.
Functional Outcome Measures: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Timed Up and Go Test, Cognitive Timed Up and Go Test, Single Leg Balance Test, and Four Square Step Test.
Digit Backwards Test : Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Measure of working memory capacity
Stroop Effect Test: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Measure of working memory and attention

Secondary Outcome Measures

Name	Time	Method
Vital Sign measurements: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Blood pressure and heart rate taken after 5 min supine, immediately upon standing, and 2 min after standing
Numeric Pain Rating Scale: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	An 11 point scale for level of pain from 0 (no pain) to 10 (severe pain).
Global Rating of Change Questionnaire: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	A 15 point global rating scale for changes in domains, from -7 (a great deal worse); through 0 (no change) to +7 (a great deal better).
Activities-specific balance confidence scale: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	A structured questionnaire that measures an individuals confidence performing daily activities. The minimum score is 0% (no confidence in balance) to 100% (complete confidence in balance).
Neurotrophic Growth Factors: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Serum concentration of brain derived neurotrophic factor and insulin-like growth factor 1
Anthropometric measurements: Change from baseline to the end of intervention/control period	Measures taken at baseline and again at approximately 9-10 weeks	Height and weight

Trial Locations

Locations (1)

The University of Texas at Austin; 🇺🇸 Austin, Texas, United States